Do you want to read an article? Please log in or register.
Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase 3 SatraGO-1 and SatraGO-2 Randomized Trials
Further Publications
Related content
Macular DiseasesRetinal Diseases
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial
Ophthalmology
Khanani AM, Danzig CJ, Heier JS, Jaffe GJ, Kaiser PK, Lally DR, Patel SS, Vajzovic L, Weng CY, Patel H, Clark J, Desai D, Luo D, Henry E, Holz FG, GATHER2 trial investigators
doi: 10.1016/j.ophtha.2025.12.011
Dry Eye Disease
Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal Studies COMET-2 and COMET-3
Ophthalmology
Pattar GR, Wirta D, Jerkins G, Paauw J, McLaurin EB, Liu A, Evans DG, Kenyon K, Cline N, Gupta PK, Meng I, Senchyna M, COMET-2 and COMET-3 study groups
doi: 10.1016/j.ophtha.2025.09.018
Macular Diseases
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial
Ophthalmology
Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Cheng Y, Bhore R, Bai Z, Schmidt-Ott U, Schmelter T, Schulze A, Hasanbasic Z, Morgan-Warren PJ, Zhang X, Hirshberg B, Yancopoulos GD, PHOTON investigators
doi: 10.1016/j.ophtha.2025.10.028
Dry Eye Disease
Efficacy and Safety of SJP-0132 in Patients with Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study
Am J Ophthalmol
Hori Y, Wada T, Omatsu K, SJP-0132 clinical study investigators
doi: 10.1016/j.ajo.2025.11.036
RECOMMENDED
Dry Eye Disease
Lifitegrast Ophthalmic Solution 5.0% (KH732) for Dry Eye Disease: A randomized, Multicenter, Double-Masked, vehicle-controlled Phase 3 Trial
★ 2
Recommended by
Prof. emer. Dr Josef Flammer, Faculty Member
Ocul Surf
Lu Y, Jin X, Li X, Jie Y, Tao L, Ren S, Zhao S, Li Y, Xu G, Zhuang W, Li Y, Chen W, Cai S, Gu H, Zhang H, Li L, You Z, Li J, Zhao J, Chen Q, Huang T, Wu P, Wang T, Yao Y, Wang H, Li Z, Shu X, Wang R, Zhang M, Wen F, Fu Y, Pei C, Zhang W, Guan H, Zhao H, Yang J, Song L, He M, Lv X, Wu F, Gong L, Sun X
doi: 10.1016/j.jtos.2026.04.006
Retinal DiseasesFurther Publications
Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: The TEASE-1 Randomized Clinical Trial
JAMA Ophthalmol
Kay CN, Saad L, DeBartolomeo G, Bressler N, Tsang SH, Stepien K, Bernstein P, Lam BL, Washington I, Gorin MB, TEASE-1 Study Group
doi: 10.1001/jamaophthalmol.2026.3662
Retinal Diseases
Faricimab for Polypoidal Choroidal Vasculopathy: 48-Week Results from the Phase 3b/4 SALWEEN Trial
Ophthalmol Retina
Cheung CMG, Lee WK, Chen SJ, Iida T, Lee J, Li X, Sun X, Ruamviboonsuk P, Koh AHC, Yanagi Y, Bai R, Duc AN, Margaron P, Lai TYY
doi: 10.1016/j.oret.2026.08.003
Retinal Diseases
Effects of Time From Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase 3 Trials
Ophthalmol Retina
Sharma S, Dhoot DS, Grewal DS, Jung E, Silva FQ, Du W, Moini H, Boyer DS
doi: 10.1016/j.oret.2026.04.027
Further Publications
Time-Varying Effects of Valacyclovir Prophylaxis in the Zoster Eye Disease Study: A Post Hoc Exploratory Analysis of a Randomized Clinical Trial
JAMA Ophthalmol
Warner DB, Lee TF, Troxel AB, Prescott C, Cohen EJ, Jeng BH, ZEDS Trial Research Group
doi: 10.1001/jamaophthalmol.2026.3202